The Right Vasopressor at the Right Time Does Early Use of Vasopressors Decrease Morbidity and Mortality in Septic Shock by Kittok, Michael
Augsburg University
Idun
Theses and Graduate Projects
2019
The Right Vasopressor at the Right Time Does
Early Use of Vasopressors Decrease Morbidity and
Mortality in Septic Shock
Michael Kittok
Augsburg University
Follow this and additional works at: https://idun.augsburg.edu/etd
Part of the Hemic and Lymphatic Diseases Commons
This Open Access Thesis is brought to you for free and open access by Idun. It has been accepted for inclusion in Theses and Graduate Projects by an
authorized administrator of Idun. For more information, please contact bloomber@augsburg.edu.
Recommended Citation
Kittok, Michael, "The Right Vasopressor at the Right Time Does Early Use of Vasopressors Decrease Morbidity and Mortality in
Septic Shock" (2019). Theses and Graduate Projects. 950.
https://idun.augsburg.edu/etd/950
  
 
 
 
 
The Right Vasopressor at the Right Time 
Does Early Use of Vasopressors Decrease Morbidity and Mortality in Septic Shock 
By 
Michael Kittok 
Meredith Wold 
 
 
 
Paper submitted in Partial Fulfillment  
Of the Requirements for the Degree 
Of Master of Science 
Physician Assistant Studies 
Augsburg University  
Right Vasopressor 2 
Table of Contents:Pages 
Abstract………………………………………………………………………………………....…3 
Introduction………………………………………………………………………………….….4-5 
Methods……………………………………………………………………………………...….5-6 
Background…………………………………………………………………………………….6-24 
Norepinephrine...……………………………………………………………………....6-12 
Vasopressin…………………………………………………………………………...12-22 
Terlipressin…………………………………………………………………………...22-27 
Early Pressors………………....……………………………………………………...27-32 
Discussion…………………………………………………………………………………….32-37 
Conclusion……………………………………………………………………………………37-38 
References……………………………………………………………………………………39-46 
  
Right Vasopressor 3 
Abstract 
Sepsis and septic shock is a disease process that carries a high mortality rate and is 
responsible for a large portion of healthcare expenditures in the United States. The Surviving 
Sepsis Campaign has been working to decrease the mortality of sepsis since 2001. Their mission 
is two-fold; providing evidence based guidelines to help direct treatment, and raising awareness 
to healthcare providers and patients about sepsis. A main goal in treating sepsis is to reverse the 
hypoperfused state by giving crystalloid fluids and administering vasopressors, specifically 
norepinephrine, after patients have received adequate fluids. Would modifying this treatment by 
giving a combination of vasopressors, instead of the current recommendation of just 
norepinephrine, earlier decrease the mortality of patients in septic shock? 
After performing a literature search on PubMed and Google Scholar, 80 articles were 
found and narrowed down to a total of 32, including randomized control trials, animal trials, 
retrospective and prospective cohort studies and meta-analyses, were reviewed. Articles looked 
at norepinephrine, vasopressin, terlipressin, dobutamine, and early vasopressor use. 
This literature review found that there is some evidence supporting the early use of 
combination vasopressor therapy, though more in-depth trials should be performed before 
making stronger recommendations or changing guidelines. Different patient subgroups appear to 
have better outcomes based on the different combinations of vasopressors. Norepinephrine 
continues to be a mainstay of treatment, and patients need to receive crystalloid fluids before and 
during administration of vasopressors.  
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Introduction 
More than 1.7 million Americans suffer from sepsis each year. ​1​ Sepsis has a high 
mortality rate calculated between 10 and 52% with mortality increasing with disease severity. ​2 
Sepsis, if unnoticed and left untreated, can quickly progress into septic shock which is very 
severe and life threatening. Septic shock is a type of distributive shock that causes the 
vasculature of a body to dilate. ​2​ This vasodilation drops the systemic vascular resistance, thereby 
decreasing cardiac output and causing a hypoperfused state for the tissues of the body. ​2​ The 
Surviving Sepsis Campaign, which is a consortium of doctors and researchers formed in 2002 
whose overarching goal is to reduce mortality from sepsis as well as provide guidelines for 
treatment, defines sepsis as “life-threatening organ dysfunction caused by a dysregulated host 
response to infection”. ​3  ​Another group working towards understanding is Sepsis 3. Sepsis 3 is 
the third international consensus of what sepsis and septic shock are, and is created by a separate 
task force of experts to have a common definition of the disease states. ​4​ It defines septic shock as 
“a subset of sepsis with circulatory and cellular/metabolic dysfunction associated with a higher 
risk of mortality”. ​4​ Septic shock is becoming more prevalent throughout the world resulting in 
increased costs of approximately $20 billion in the United States in 2011 alone. ​4​ Improving 
management and updating the guidelines for the care of sepsis and septic shock could help to 
decrease mortality in vulnerable patients and help lower healthcare costs. 
The Surviving Sepsis Campaign came out with their most recent guidelines for the 
treatment of septic shock in 2016 but provides updates to these guidelines in order to account for 
new findings with the goal to continually improve care. ​3​ These new guidelines recommend 
treatment start with the goal of obtaining a Mean Arterial Pressure (MAP) of greater than 
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65mmHg. ​3​ The first step in obtaining this goal is a crystalloid fluid bolus of 30 mL/Kg within the 
first 3 hours of the onset of septic shock followed by more boluses of crystalloid fluid. ​3​ The use 
of norepinephrine as the first line vasopressor for fluid resistant septic shock is recommended 
next, followed by the addition of other vasopressors including vasopressin, epinephrine, 
dobutamine and dopamine. ​3  
Although this is the current recommendation, there are many adverse reactions that can 
occur with this particular treatment regimen for septic shock. Aggressive fluid resuscitation can 
cause dire complications from volume overload including pulmonary edema requiring the patient 
to be placed on ventilator support. ​5​ Vasopressor use also has a downside, with many patients 
having a wide variety of unwanted adverse reactions including but not limited to arrhythmias, 
and digital and cardiac ischemia. ​3,6​ In light of new research, the Surviving Sepsis Campaign 
released an update in 2019 which includes the Hour-1 Bundle moving the use of vasopressors 
into the first hour of resuscitation, if clinically indicated, to help combat or preemptively treat 
some of the known adverse reactions. ​5​ Does earlier use of combination vasopressors decrease the 
morbidity and mortality of patients with septic shock compared to the previous standard of care 
of a fluid bolus followed by the use of vasopressors? 
Methods 
A literature search was completed using PubMed and Google Scholar. The key words 
included in the search were, “Sepsis”, “Septic Shock”, “Vasopressors”, “Norepinephrine”, 
“Vasopressin”, “Crystalloid”, and “Resuscitation.” A search of the references from these articles 
also produced more literature. Originally 80 articles were selected, these were further narrowed 
down.  The vast majority of articles were published within the last 10 years. One trial was 
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published 11 years ago but deemed necessary due to it being viewed and used as foundational in 
current literature and trials. Inclusion criteria for this systematic review included evaluating 
conflicts of interest of the authors, evaluating study designs, and assessing the authors’ 
interpretation of their data sets. There are five articles that evaluated norepinephrine dosing, six 
articles comparing the use of different doses of norepinephrine to the use of norepinephrine in 
combination with other vasopressors, twelve articles comparing the use of vasopressin with and 
without norepinephrine to the use of norepinephrine alone, seven articles that compared the use 
of terlipressin with and without norepinephrine to norepinephrine alone, and six articles 
comparing early use of vasopressors to later use. Randomized control trials, retrospective 
observational non-interventional studies, nested cohort studies, prospective observational studies, 
prospective interventional trials, meta-analyses, and animal trials were all included. Each article 
was reviewed individually and information was collected specifically for this review. Also 
reviewed were the previous and current recommendations from the Surviving Sepsis campaign to 
see the evolution of care. 
Background 
Norepinephrine  
Surviving Sepsis Campaign has recommended norepinephrine as the first-line 
vasopressor in their guidelines since 2008. ​6​ Their recommendation for this intervention has only 
increased in strength since the first guidelines were published due to their analyses of recent 
trials and studies. ​3,7​ The goal of treatment associated with adding a vasopressor is to attain a 
MAP greater than 65mmHg. ​3,5-7​ MAP is an important measurement of the pressure at the level of 
the organs and if it falls too low the organs are not perfused. ​3​ If an organ is not perfused, the cells 
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start to die, and the tissues and organs are not able to function. ​3​ A MAP below 65mmHg is 
associated with the hypoperfusion of organs and higher mortality since inadequate amounts of 
oxygen is being delivered. ​3​ Norepinephrine is a catecholamine that is both an alpha and beta 1 
agonist. ​8​ It acts as a strong alpha agonist causing vasoconstriction, which increases systemic 
resistance and, in turn, blood pressure. ​8​ It also acts as a weak beta 1 agonist, having inotropic and 
chronotropic effects. ​8​ Adverse reactions include arrhythmias, bradycardia, peripheral vascular 
insufficiency and peripheral ischemia. ​8  
Norepinephrine is an effective vasopressor, especially in patients that are severely 
hypoperfused. A prospective observational study by Chen et al followed 372 patients with acute 
kidney injuries from septic shock. ​9​ The study tracked the amount and frequency of the 
vasopressors they received and patients’ 90 day mortality after dialysis was started. ​9​ The study 
found no statistical difference in mortality rates between the norepinephrine group when 
compared to the non norepinephrine group, which included the use of other vasopressors such as 
dopamine, dobutamine, epinephrine, isoproterenol and milrinone. ​9​ Even though there was no 
significant change in mortality, this study did find that patients receiving norepinephrine spent a 
statistically significant less amount of time on dialysis compared to the non norepinephrine 
group. ​9​ This is particularly interesting since the norepinephrine group was comprised of more 
severely ill patients with significantly higher Sequential Organ Failure Assessment (SOFA) 
scores. ​9​ SOFA scores are a measurement tool used in intensive care units (ICU) to help predict 
mortality based on the function of organ systems, including cardiovascular, respiratory, hepatic, 
neurologic, renal and coagulation. ​2 
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Similarly, a meta-analysis reviewed 14 studies including a total of 2811 patients who 
received vasopressors for septic shock. ​10​ Oba and Loan looked at the benefit and effectiveness of 
different vasopressors in septic shock. ​10​ They concluded that norepinephrine and norepinephrine 
with low dose vasopressin can decrease 28 day mortality when compared to patients receiving 
dopamine alone. ​10​ In their analysis, they concluded that dopamine should not be completely 
ruled out as a treatment option as it may have a place in treating patients with a low risk of 
arrhythmias. ​10​ Another meta-analysis of 43 randomized control trials with a total of 5767 patients 
in septic shock evaluated the effects of vasopressors on adverse reactions and 28 day mortality. ​11 
Cheng et al found more incidences of arrhythmias with dopamine, 26.01%, epinephrine, 22.98%, 
norepinephrine with dobutamine, 20.6%, as compared to norepinephrine alone, 8.33%, and 
vasopressin, 1.67%. ​11​ In this analysis there was a decrease in mortality when adding dobutamine 
to norepinephrine. ​11​ The combination therapy of norepinephrine and vasopressin was associated 
with shortened hospital stays for patients. ​11​ Finally, the analysis found that when terlipressin was 
added to norepinephrine it decreased ICU mortality for patients with sepsis compared to the use 
of other vasopressors in similar patients. ​11​ Based on these studies norepinephrine continues to be 
an effective vasopressor and is justified as the first line treatment in the Hour-1 Bundle for 
combating hypoperfusion and its associated complications for patients with septic shock as stated 
in the guidelines. ​3,9,10,11  
Not covered in the most recent Surviving Sepsis Campaign’s guidelines is the 
recommended dosing of norepinephrine to attain the MAP goal. Per UpToDate, the 
recommended dose to treat septic shock is 0.01-3 mcg/kg/min. ​8​ There does not appear to be a 
consensus for dosing, though many studies are showing high doses of norepinephrine is 
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associated with increases in morbidity and mortality. Many studies and trials are trying to 
pinpoint what should be considered a high and low dose. 
There has been much speculation and debate about how much norepinephrine is too 
much. A retrospective study by Chou et al out of China in 2011 reported that doses greater than 
0.3mcg/kg/min significantly increased mortality for patients. ​12​ The higher dosage showed a 
mortality of 93.5% compared to 66.4% (p<0.001) for patients receiving less than 
0.3mcg/kg/min. ​12​ This study had a high overall mortality, which was attributed to the high 
prevalence of severe acute kidney injury documented by a drastic decrease in average urine 
output, 0.3 L/24hrs, and elevated serum creatinine, 4.8+/-4.1 mg/dL. ​12​ The researchers followed 
the patients for 60 days after treatment, noting that 97.5% of the patients died before 60 days and 
2% dying after the 60 days, leaving only .5% as survivors. ​12​ The main focus of Chou et al’s 
study was looking at the results of continuous renal replacement therapy (CRRT) in critically ill 
patients receiving high doses of vasopressors. ​12​ Patients who did not require CRRT were not 
included in this study. Crystalloid fluid therapy is not mentioned, and it is unknown if this played 
any role in this retrospective observational study.  
On a similar note, Martin et al performed a retrospective, non-interventional, 
observational study looking at ICU patient charts over a 4 year period and evaluated their 90 day 
mortality. ​13​ The study showed that a norepinephrine dose of greater than 1mcg/kg/min is linked 
to higher mortality, up to 90%, for patients experiencing septic shock. ​13​ The higher dose was 
associated with higher mortality compared to lower doses of norepinephrine, but interestingly the 
link between higher mortality and high doses of norepinephrine had death occurring during the 
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infusion. ​13​ If patients survived the original high dose infusion of norepinephrine, the mortality 
rate remained consistent with other, lesser dosages. ​13  
Defining what is considered a high dose of norepinephrine has been difficult to 
determine. Auchet et al conducted a retrospective observational study looking for predictors of 
mortality in patients experiencing septic shock. ​14​ They found a high predictive value of mortality 
when high dose norepinephrine is given to a patient who already has a high SOFA score. ​14​ This 
study looked at the total doses of vasopressors divided by the total time they were given and 
came out with a weight based mean dose. ​14​ Their data showed a weight based mean dose of 0.75 
mcg/kg/min, as the high dose, has a good predictive value of mortality with a sensitivity of 73% 
and a specificity of 74%. ​14​ They also looked at maximum dosage given, and most survivors in 
this study had received a maximum dose of less than 2.3 mcg/kg/min at some point during their 
care. ​14​ The max dose had a smaller predictive value compared to the weight based mean dose. ​14 
This study did have a smaller 90 day mortality rate, 60%, compared to other high dose 
norepinephrine studies. ​14  
A nested cohort study in the Dexmedetomidine for Sepsis in Intensive Care Unit 
Randomized Evaluation (DESIRE) trial by Yamamura et al considered a high dose of 
norepinephrine as greater than 416 mcg/kg/week. ​15​ This dose averaged out to 0.04 mcg/kg/min 
though they were looking at total norepinephrine given over the first week of treatment, not just 
individual doses. ​15​ Both arms of the study, a high dose and a low dose group, received boluses of 
crystalloid fluids before starting vasopressors. ​15​ The high dose group did require higher doses of 
supplemental vasopressors (dobutamine and vasopressin), required more crystalloid fluid both in 
day 1 and day 2 of treatment, and had less ventilator free days when compared to the low dose 
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group. ​15​ There was no difference in mortality between the two groups. ​15​ Again, this study looked 
at total norepinephrine dose over a week not individual doses, but based on their graphs the 
highest dosage was given on day 2 of treatment with approximately 300 mcg/kg/day given, 
which averages out to a dose of 0.2 mcg/kg/min. ​15​ This amount is still well below the high doses 
used in other studies that considered at least 1 mcg/kg/min as its high dose. ​12-15​ Chen et al looked 
at patients with acute kidney injuries from septic shock, vasopressors they received, and 90 day 
mortality after dialysis was started. ​9​ The study showed norepinephrine may have a detrimental 
effect on severely ill patients with acute kidney injury following septic shock, but survivors who 
received norepinephrine tended to spend less time on dialysis. ​9​ The researchers also found that 
this increase in mortality was dose dependent and also took into account an increase in adverse 
effects associated with higher doses of norepinephrine. ​9 ​There is a lack of agreement as to what 
constitutes a high dose of norepinephrine, but it is observed that higher doses are linked to 
increased risks of adverse effects that are tied to higher mortality. ​9,12-14​ There is no consensus on 
what constitutes a high dose of norepinephrine but there is sufficient evidence that higher 
mortality is associated with elevated doses of norepinephrine, but what constitutes a high or low 
dose is not the only factor to consider when looking at norepinephrine use. 
With higher mortality and morbidity associated with higher dose norepinephrine, are 
there certain patient populations that affect the pharmacokinetics and pharmacodynamics of 
norepinephrine and require different doses or combinations of vasopressors? A retrospective 
cohort study performed by Bauman et al did a 2 year review of 159 patients in septic shock who 
required vasopressors. ​16​ This study found that racial differences can affect how a patient will 
respond to different vasopressors. ​16​ The data showed that with similar severity of sepsis and 
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similar pre-vasopressor treatments, African Americans require higher doses of norepinephrine 
when compared to Caucasians, 21.08 mcg/hr versus 12.37 mcg/hr (p<0.01) respectively. ​16​ This 
study looked at total doses ​16​ and did not show weight based dosing, which is how norepinephrine 
is normally dosed. They also found that the African American patients had a statistically 
significant higher prevalence of pre-existing hypertension, 68.3% versus 31.7% (p=0.007), and 
end stage renal disease, 85.7% versus 14.3%( p=0.011), when compared to similar Caucasian 
patients. ​16​ The source of the infections that caused the patients to go into septic shock were also 
significantly different. ​16​ Bloodstream infections were more frequent in African Americans, 8.2% 
versus 0.6% p=0.017, while abdominal infections were more prevalent in Caucasians, 13.8% 
versus 10.7% p=0.008.​16​ Though severity of septic shock was comparable between the two 
groups, source of infection and preexisting conditions may alter how the disease progresses 
therefore changing the treatment. That said, racial differences and medical histories appear to 
play a role in how a patient responds to treatment.  
Norepinephrine is very effective as a first line vasoconstrictor in the treatment of septic 
shock. ​3​ There is no upper limit of dosing listed in the guidelines, and there does appear to be a 
risk of increased morbidity and mortality associated with higher dose infusions of 
norepinephrine. ​3,9,12-15​ The use of other vasopressors, like vasopressin, in conjunction with or 
apart from norepinephrine, have been studied to see if there are better treatment plans available 
that could decrease these risks in patient populations. There is evidence that when patient 
situations and patient populations are considered there are different combinations of treatment 
options that may increase the likelihood of a positive outcome. 
Vasopressin  
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The current Surviving Sepsis Campaign guidelines weakly recommend adding 
vasopressin to norepinephrine to either increase MAP to the target goal or to decrease the 
norepinephrine dosage that is tied to higher mortality. ​3​ Vasopressin is an antidiuretic hormone 
analog that binds to arginine vasopressin (AVP) receptors. ​17​ There are two types of AVP 
receptors, V1 and V2. V1 increases systemic vascular resistance, and V2 increases aquaporin 
production in the renal tubule increasing water reabsorption, both of these work to increase tissue 
perfusion. ​17​ While vasopressin treatment has shown to increase MAP, there are multiple reasons 
to be cautious and why this is only a weak recommendation. ​3,17​ Adverse effects include atrial 
fibrillation, ischemic heart disease, myocardial infarction, limb ischemia, hyponatremia, renal 
insufficiency, increased serum bilirubin, and decreased platelet count. ​3,17​ Vasopressin can be 
used as part of a combination therapy with norepinephrine or potentially as an initial 
monotherapy, though there are concerns about adverse reactions when using vasopressin alone or 
in combination therapies and how timing of administration affects these effects. 
One of the potential adverse effects of vasopressin use is cardiac ischemia, which is 
normally diagnosed with a 12 lead electrocardiogram (ECG) and elevated troponin and CK-MB 
levels. Mehta et al performed a prospective sub study as part of the VASST study. ​18​ They 
specifically looked at troponin levels, CK-MB levels, and 12 lead ECGs as markers for cardiac 
ischemia in the 121 patients who received either a low dose of vasopressin, 01-0.3 U/min, or 
norepinephrine, 5-15 mcg/min, after already receiving 5 mcg/min of norepinephrine. ​18​ There was 
no difference in the elevation of troponin  and CK-MB levels between the two groups in this 
substudy.​18​  The only difference between the two groups on the 12 lead ECG was that the 
norepinephrine monotherapy group had a higher presence of Q waves, 26% versus 18% p=0.039, 
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compared to the vasopressin group. ​18​ Q waves can be a sign of cardiac ischemia. There was no 
statistical difference in the presence of ST segment elevation, ST segment depression or T-wave 
inversion. ​18​ There was no correlation found during this study with the presence of cardiac 
ischemia and increased mortality. ​18​ Although cardiac ischemia is a concern with the use of 
vasopressin, vasopressin paired with norepinephrine does not appear to be more responsible at 
causing cardiac ischemia when compared to the use of norepinephrine alone. Making sure that 
the patient does not already have a history of acute coronary syndrome or severe heart failure is 
vital before administration. 
Russell et al performed the Vasopressin and Septic Shock Trial (VASST) to see if a low 
dose infusion of vasopressin administered in combination with norepinephrine decreased 
mortality compared to patients being treated with norepinephrine alone. ​19​ They analyzed 778 
patients who had been randomized into the trial. ​19​ VASST looked at 0.01-0.03 U/min infusions 
of vasopressin given with 5 mcg/min of norepinephrine compared to patients receiving only 
norepinephrine at 5-15 mcg/min. ​19​ There was no significant change in mortality at 28 days, 
35.4% versus 39.3%(p=0.26), or at 90 days, 43.9% versus 49.6% (p=0.11) between the 
vasopressin and norepinephrine groups respectively. ​19​ There was also no statistical difference 
between the amount or severity of adverse reactions between the two groups, 10.3% in the 
vasopressin group and 10.5% in the norepinephrine group (p=1.00). ​19​ Though not statistically 
significant, there were more incidences of cardiac arrests in the norepinephrine group and more 
incidences of digital ischemia in the vasopressin group. ​19​  It is important to note that the study 
did exclude patients if they had a known history of acute coronary syndrome or severe heart 
failure since these conditions are both known to worsen with vasopressin administration. ​19​ An 
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interesting aspect about this study was that the baseline MAP for patients studied was between 
72-73 mmHg, already in the target range of 65-75mmHg. ​19​ The authors note that as the study 
progressed it became more of a norepinephrine sparing study as opposed to unresponsive to 
norepinephrine study as originally intended. ​19​ The VASST study found that combination therapy 
is not superior to norepinephrine monotherapy. ​19​ VASST evaluated the use of low doses of 
vasopressin in patients who had already achieved the MAP goal ​19​, but the authors cede that there 
are other doses and other times that vasopressin could and should be administered to promote 
positive treatment results.  
One such instance is higher dose vasopressin combination therapy may be more effective 
than low dose vasopressin monotherapy at treating septic shock. Torgersen et al performed a 
randomized control open label trial to compare and determine effective dosing of vasopressin. ​20 
The two doses used were 0.033 and 0.067 U/min as part of combination therapy with 
norepinephrine at a dose of at least 0.6 mcg/kg/min. ​20​ Patients were given the combination 
therapy for a total of 48 hours. ​20​ This was a small study with 50 total patients randomized. ​20​ The 
researchers noted that the patients in the higher dose group had a greater reduction in 
norepinephrine doses at 48 hours 0.22 +/- 0.16 mcg/kg/min in the high dose vasopressin group 
and 0.4 +/- 0.31 mcg/kg/min in the low dose group (p=0.006). ​20​ Troponin levels were also 
significantly lower in the higher dose vasopressin group 0.22 +/-0.41 mg/dL compared to 1.77 
+/- 4.8 mg/dL (p=0.03). ​20​ Another adverse reaction of vasopressin is a fall in platelet counts. In 
this study the low dose vasopressin group had a statistically significant drop (p=0.02) in platelets 
while the high dose group did have a drop, although it was not statistically significant (p=0.18). ​20 
Mortality rates were not affected between the two treatment groups, ICU mortality was 40% in 
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the low dose versus 52% in the high dose (p=0.57), and 28 day mortality was 52% (p=1) for both 
groups.​20​ Vasopressin as used in combination therapy appears to be more effective in higher 
doses at increasing and maintaining MAP, thereby decreasing the amount of norepinephrine 
needed. ​20​ The adverse reactions were also decreased in the higher dose vasopressin group 
compared to the low dose group. ​20​ Dosing of vasopressin does appear to affect its effectiveness 
in reversing hypoperfusion in septic shock. Another important factor that health care providers 
should consider as it could change how well a patient responds to vasopressin is the timing of 
administration. 
Russel et al reevaluated their data from the VASST study after the new Sepsis 3 criteria 
came out, evaluating it based on the new criteria for sepsis. ​21​ The Sepsis 3 criteria requires that 
septic shock be identified when a patient displays “persistent hypotension requiring vasopressors 
to maintain a MAP greater than 65 mmHg and having a serum lactate greater than 2 mmol/L 
despite adequate volume resuscitation.” ​4,21​ Bringing in the new requirement for a lactate greater 
than 2 mmol/L reduced the sample size from VASST, but the new sample still showed no 
significant difference in mortality for the norepinephrine plus vasopressin group compared to the 
norepinephrine alone group. ​21​ The researchers did find that patients that were treated according 
to the older inclusion criteria who had a lactate level less than or equal to 2 mmol/L had a 
significantly lower mortality in the vasopressin group compared to the norepinephrine group at 
both 28 days, 27.2% versus 36.6% (p=0.086), and at 90 days, 35.6% versus 47.9% (p=0.036). ​21 
This reanalysis of the data exposes a subset of patients that may benefit from early combination 
therapy. 
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Since the VASST trial reanalysis exposed a subset of patients that may benefit from the 
combination therapy of norepinephrine and vasopressin ​21 ​Sacha et al performed a retrospective 
review looking to identify other predictors of that could show which patients might benefit from 
the combination therapy. ​22​ This review looked at 938 ICU patient charts to evaluate who 
responded to vasopressin by achieving a MAP greater than 65mmHg at 6 hours post vasopressin 
infusion. ​22​ The researchers noted a 45% response rate to a fixed dose, 0.03 U/min, of 
vasopressin. ​22​ The group of patients that responded to vasopressin had a decrease in mortality, 
56.6% versus 71.7% (p<0.001)​22​,  and a decrease in the dosage of norepinephrine needed. ​22​ They 
also noted that patients with a lactate of less than or equal to 1.4 mmol/L were more likely to 
respond to vasopressin (p<0.001). ​22​ Vasopressin is effective overall but it is shown to be even 
more effective when patients are not already in a state of severe septic shock. 
In addition to lactate levels, there are other potential predictors of vasopressin response. 
Nascente et al performed a small prospective interventional study with 18 patients. ​23​ The study 
included patients in septic shock who had already received crystalloid fluid boluses and 
norepinephrine, the patients then received a vasopressin dose of 0.04 U/min and infused patients 
for 1 hour followed by 48 hours of observation. ​23​ The evaluators obtained sidestream dark field 
imagery of the sublingual microvasculature and compared three images; one from before 
treatment, another from 1 hour after the initial vasopressin infusion, and the last from 2 hours 
after the infusion. ​23​ The researchers reported that 50% of the patients had microvascular response 
to vasopressin and classified these patients as responders. ​23​ Both groups, the responders and 
nonresponders, had a decrease in the norepinephrine dose required to maintain a MAP greater 
than 65 mmHg during the 1 hour infusion of vasopressin. ​23​ However, the study found that the 
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nonresponders had a need for a significant increase in norepinephrine dosing after the cessation 
of the vasopressin infusion to maintain a MAP of 65 mmHg or greater. ​23​ The responders did not 
have a similar need for an increase in norepinephrine. ​23​ The researchers also found that patients 
who are receiving higher doses of norepinephrine before the administration of vasopressin are 
more likely to have a microcirculatory response to vasopressin, specifically patients receiving 
norepinephrine doses above 0.38 mcg/kg/min. ​23​ They assigned a predicted probability of 53% 
with a sensitivity of 78% and a specificity of 77%. ​23​ ​Although this study helped to predict who 
would respond to vasopressin combination therapy, there were many shortcomings that make 
drawing definitive conclusions challenging including a restrictively small sample size with no 
randomization nor control ​. The study looked only at the results of the infusion of vasopressin for 
a short period of time and no long term effects were followed. ​23​  Predicting who will respond to 
the combination therapy is very important, providers do not want to waste valuable time and risk 
adverse reactions if it is known a patient will not respond to the therapy. More studies need to be 
completed and analyzed to strengthen current guidelines and recommendations. 
Studies are finding that there are patients who respond with the addition of vasopressin to 
norepinephrine and those who do not respond. Timing may be a confounder affecting who 
responds. Hammond et al performed a prospective open label trial testing if early dosing of 
norepinephrine with vasopressin decreased morbidity and mortality compared to norepinephrine 
monotherapy. ​24​ Over two separate 4 month periods, the evaluators added patients who were in 
septic shock and had received at least 30mL/kg fluid bolus in the previous 4 hours of treatment 
into the study. ​24​ In the first 4 month period patients were treated with norepinephrine starting at 
5mcg/min. ​24​ The primary outcome of the study was to find the amount of time needed to achieve 
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a MAP of 65 mmHg and then maintain it for 4 hours. In the norepinephrine monotherapy 
portion, a failure was considered an inability to achieve or maintain a MAP of 65 mmHg with a 
dose of up to 15mcg/min. ​24​ In the second study period, patients were started on 5mcg/min of 
norepinephrine and then given vasopressin at a dose of 0.04 U/min within 4 hours of starting the 
norepinephrine. ​24​ Norepinephrine was then titrated up to achieve and maintain the MAP goal. ​24​ If 
unable to achieve or maintain the MAP with a norepinephrine dose of 15 mcg/min, the dual 
therapy was considered a failure. ​24​ A total of 82 patients, 41 in each group were analyzed. ​24​ Both 
groups had elevated lactate levels, greater than 4 mmol/L. ​24​  They found that early use of 
vasopressin decreased the time it took for patients to reach and maintain a MAP greater than 
65mmHg when compared to the norepinephrine monotherapy group, 5.7 hrs versus 7.6 hrs 
(p=0.058).​24​ Vasopressin was used as a secondary vasopressor in 46% of the patients in the 
monotherapy group. ​24​ In this study, the adding of vasopressin to norepinephrine within 4 hours 
of onset of septic shock was more effective at achieving and maintaining the MAP goal. ​24​ The 
researchers did not show any difference in mortality, hospital stay length, or new onset of 
arrhythmias between the two groups. ​24​ It also appears that elevated lactate levels did not affect 
the effectiveness of vasopressin in this study. ​24  
A small retrospective cohort analysis performed by Reardon et al looked at early versus 
late delivery of vasopressin in septic shock. ​25​ Early delivery was defined as less than 4 hours 
after the start of norepinephrine. ​25​ The dose of vasopressin in this review was 0.04 U/min. ​25​ The 
researchers found a significant decrease in the number of new onset arrhythmias noted in the 
early administration group compared to the late group, 37.1% versus 63.9% (p<0.001) 
respectively. ​25​ The most common new arrhythmia was atrial fibrillation with rapid ventricular 
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response. ​25​ There was no noticeable difference between the amount and duration of 
norepinephrine used. ​25​ Another finding, though not statistically significant, was a trend of 
elevating troponin (p>0.05) and CK-MB (p>0.05) in the late administration of vasopressin. ​25 
These studies demonstrate that the early use of combined norepinephrine and vasopressin is able 
to achieve targeted MAP goals earlier than norepinephrine monotherapy. ​24,25​ Early combination 
therapy also shows a decrease in adverse effects like the amount of arrhythmias and possibly a 
decrease in cardiac ischemia when compared to late use of vasopressin. ​24,25 
Vasopressin combination therapy has been shown to lower the risks of cardiac 
problems, ​24,25​ though dosing may affect its effectiveness. ​26​ Russell, Wellman, and Walley 
evaluated mortality rates between norepinephrine and combination therapy of norepinephrine 
and vasopressin, looking at rates both before and after the VASST study was performed at their 
hospital. ​26​ This retrospective matched cohort study found that before the VASST trial, 
combination therapy of norepinephrine and vasopressin had a higher 28 day mortality rate 
compared to norepinephrine alone, 60.8% versus 46.2% (p=0.009). ​26​ After the trial the mortality 
rates of patients receiving combination therapy were comparable to the monotherapy patients, 
31.2% and 26.9%. ​26​ Since this is a retrospective cohort study, they did not find a cause for this 
change in mortality. The authors speculate that it could have been due to a decrease in the 
amount of initial vasopressin given after the VASST study, 0.032 U/min post VASST and 0.036 
U/min (p=0.001) pre VASST.​26​ Another possible cause could have been that benefits of 
treatment outweighed any adverse events, which they did not assess. Also postulated is that the 
providers may have been more aware of the guidelines of when to use vasopressin and when not 
to based on the severity and circumstances of the patient. ​26​ Either way, it is very interesting that 
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the mortality rates changed after the study, and that habits of prescribing vasopressin changed as 
well. 
With changing the dosing and timing of vasopressin and norepinephrine combination 
therapy, it has shown to be superior to norepinephrine monotherapy at reversing the 
hypoperfused patient in septic shock. ​20-25​ Vasopressin is effective as an adjunctive vasopressor 
and vasopressin may be just as effective as norepinephrine if used as monotherapy. The 
vasopressin versus norepinephrine as initial therapy in septic shock (VANISH) trial evaluated the 
use of vasopressin as monotherapy compared to norepinephrine. ​27​ This was a double blinded, 
randomized clinical trial with vasopressin doses up to 0.06 U/min and norepinephrine doses up 
to 12 mcg/min. ​27​ Open label use of norepinephrine was used as a supplement vasopressor when 
patients were maxed out on study medication and still had not reached a MAP of 65 mmHg. ​27 
They also tested giving hydrocortisone versus a placebo to patients, creating a total of 4 arms to 
this study. ​27​ There were 408 patients who were analyzed from the initial 421 who were 
randomized. ​27​ They noted no difference in mortality between the groups that received 
norepinephrine, 27.5%, and vasopressin, 30.9%, at 28 days. ​27​ The patients treated with 
vasopressin had a lower rate of needing renal replacement therapy, 25.4% versus 35.3%. ​27​ Also 
of note is that the use of vasopressin compared to norepinephrine did not affect the amount of 
new onset organ failure or the amount of organ failure free days. ​27​ The total amount of open label 
norepinephrine use was lower in the vasopressin group when compared to the norepinephrine 
group, while MAP measurements had no significant difference between the two groups. ​27​ Initial 
vasopressin monotherapy did not improve or worsen mortality compared to norepinephrine 
monotherapy and was just as effective at maintaining MAP. 
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Vasopressin is currently recommended as an adjunctive medication for patients not 
reaching or maintaining a MAP goal of 65 mmHg on norepinephrine alone. ​3​ There is evidence 
showing that there are patient populations that may benefit from the addition of vasopressin to 
norepinephrine in a combination therapy. ​20-25​ There is also an indication from the evidence 
collected that the earlier the combination therapy is started, the more effective the treatment is at 
fighting the hypoperfused state. ​20-25​ Along with the support for combination therapy of 
vasopressin and norepinephrine, there is data that validates that initial monotherapy of 
vasopressin is as effective as norepinephrine monotherapy. ​27​ Vasopressin is not the only 
antidiuretic hormone analog, terlipressin is another analog that may be effective in reversing the 
hypoperfusion associated with septic shock and may not carry the same risks of adverse effects 
as vasopressin. 
Terlipressin 
Terlipressin is a long acting antidiuretic hormone analog that is selective for the V1 
receptor. Terlipressin is currently unavailable in the United States, but it is in a phase 3 clinical 
trial for hepatorenal syndrome type 1. ​28​ Terlipressin is used elsewhere in the world for ​treatment 
of hepatorenal syndrome and hemorrhaging esophageal varicies. ​29,30  
Terlipressin has been used in animal studies and has shown its effectiveness as a 
vasopressor in the treatment of septic shock. Ishikawa et al gave bolus injections of terlipressin 
to sheep that were in septic shock. ​29​ The two study arms consisted of a single 1mg bolus and a 
1mg bolus followed by two sequential boluses of 0.5mg every 2 hours. ​29​ They found that 
terlipressin was able to return the MAP to the target level but caused decreased coronary and 
mesenteric blood flow, as well as worsening hyperlactatemia and hypokalemia. ​29​ Kampmeier et 
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al compared giving terlipressin at 2 mcg/kg/hr either as first line vasopressor, or as a second line 
after norepinephrine exceeded dosing of 0.5 mcg/kg/min and a 0.9% sodium chloride infusion. ​30 
This study used sheep that were put into septic shock and the intervention period was only 24 
hours.​30​ There was no difference in 24 hr mortality, change in norepinephrine, or fluid 
requirements. ​30​ The animal studies showed that terlipressin is an effective tool to increase MAP 
in septic shock and reverse the hypoperfused state, but that there were also possible serious and 
severe adverse effects that need to be further evaluated. ​29,30 
 Two studies evaluated the effectiveness of terlipressin compared to norepinephrine as 
initial monotherapy in septic shock. Adverse effects were more serious and prevalent in these 
studies, ​31,32​ confirming what was found in the animal trials. ​29,30​ Choudhury et al discovered that 
terlipressin had more incidences of adverse effects, 40.5% versus 21.4% (p=0.06), compared to 
norepinephrine. ​31​ 28 day mortality was comparable between terlipressin, 73.8%, and 
norepinephrine, 85.7% (p=0.17). ​31​ Lui et al also found the terlipressin group did have a higher 
percentage of serious adverse effects, 30% compared to the 11.65% in the norepinephrine group 
(p<0.01).​32​ Digital ischemia was found to be the singular significantly increased adverse effect in 
the terlipressin group, 12.6% versus 0.35% (p<0.0001). ​32​ These two studies illustrate that there 
can be increased morbidity with the use of terlipressin monotherapy, when compared to 
norepinephrine monotherapy. ​31,32 
Even with the increased adverse effects, terlipressin was still shown to be effective in 
animal studies ​29,30​and appears to be an effective vasopressor for humans in septic shock. 
Choudhury et al performed a randomized open label trial comparing terlipressin to 
norepinephrine as a first line vasopressor for patients with cirrhosis and septic shock who are 
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unresponsive to fluid boluses after 2 hours. ​31​ This was a small study with a total of 84 patients. ​31 
The researchers found that patients in the terlipressin group were able to obtain a MAP greater 
than 65 mmHg within 48 hours; better than the norepinephrine group, 95.2% versus 71.4% 
(p=0.003).​31​ Something else of note, though not statistically significant, is that the terlipressin 
group had a higher lactate clearance (p=0.06) and improved tissue perfusion compared to the 
norepinephrine group. ​31​ Lactate clearance was able to help predict mortality. ​31​ Lactate clearance 
decline noted at 12 hours was statistically significant in patients who died compared to patients 
who survived at 28 days, 58% versus 4% (p=0.01). ​31​ The terlipressin group also had a trend 
towards reversing acute kidney injuries on day 5, 37.5% versus 8.3% (p=0.08). ​31​ Also noted in 
the study was that patients in the norepinephrine group had a significantly higher incidence of 
variceal bleeding compared to the terlipressin group, 9.5% versus 0% (p=0.01). ​31​ This 
information may help to identify patient populations that would benefit from the use of 
terlipressin as opposed to norepinephrine.  
Liu et al performed a randomized double blinded control trial that compared terlipressin 
to norepinephrine use as the initial vasopressor for the treatment of septic shock. ​32​ The study had 
two treatment groups. Patients who were still hypotensive despite adequate fluid resuscitation 
were given either terlipressin at 20-160 mcg/hr or norepinephrine at 4-30 mcg/min. ​32​ The study 
was stopped after 50% recruitment due to interim results falling into the futility region for the 
study.​32​ There were 526 patients that were analyzed for this study. ​32​ They found no difference in 
mortality between the terlipressin and norepinephrine groups, 40% versus 38% (p=0.633). ​32​ Both 
groups had similar improvement in their 7 day SOFA scores, decreasing by 7 in the terlipressin 
group and 6 in the norepinephrine group (p=0.123). ​32​ Days without vasopressors were also very 
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similar, 14.66 days for terlipressin and 15.5 days for norepinephrine (p=0.424). ​32​ Terlipressin 
appears to work as effectively as norepinephrine at reversing the hypoperfused state, and may be 
a better choice for first line treatment with certain patient populations, this should be tempered 
with the fact that more adverse effects were noted with terlipressin and it is still not cleared to be 
used on humans in the United States. ​31,32  
Vasopressin is recommended as an adjunct to norepinephrine according to Surviving 
Sepsis Campaign guidelines. ​3​ With terlipressin being a long acting, selective V1 agonist it may 
be a better medication to use as in combination with norepinephrine instead of vasopressin. Xiao 
et al executed a small randomized control trial that tested low dose terlipressin, 1.3 mcg/kg/hr, 
after the patients had received norepinephrine 0.5 mcg/kg/min compared to patients receiving 
only norepinephrine to maintain a MAP greater than 65 mmHg. ​33​ There were 32 patients 
enrolled. ​33​ This study found that the terlipressin group had a steady decline in the amount of 
norepinephrine needed after 2 hours compared to the norepinephrine monotherapy group which 
needed continued dosage increases in order to maintain a perfused state. ​33​ The MAP in the 
terlipressin group continued to be maintained above 65mmHg whereas the norepinephrine 
monotherapy group started to drop after 2 hours. ​33​ The 6 hour resuscitation goal of maintaining 
MAP above 65 mmHg was achieved at a higher rate in the terlipressin group compared to 
norepinephrine group, 73.3% versus 47.1% (p<0.01). ​33​ The 7 day survival was also significantly 
better in the terlipressin group, 66.7% versus 23.5% (p<0.01) in the norepinephrine group. ​33 
Serious adverse reactions occurred in 47% of the patients in the combination therapy group and 
82.3% of the norepinephrine monotherapy group. Higher incidences of acute renal failure and 
adult respiratory distress syndrome occurred in the norepinephrine monotherapy group, which 
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likely helped curb the mortality rate in the terlipressin group. ​33​ A continuous low dose infusion 
of terlipressin appears to improve patient outcomes and has lower adverse effect rates, though 
this was a very small study and only followed for 7 day mortality. ​33 
Terlipressin as combination therapy with norepinephrine has some support showing that 
it is more effective than norepinephrine monotherapy, ​33​ terlipressin is also as effective as 
vasopressin and norepinephrine combination therapy at treating septic shock. ​34 ​Morelli et al 
conducted the continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP) 
randomized control pilot study looking at combination therapy of terlipressin 1.3 mcg/kg/hr plus 
norepinephrine compared to vasopressin 0.03 U/min plus norepinephrine compared to a 
monotherapy treatment of norepinephrine 15mcg/min. ​34​ This was a small study with 15 patients 
in each group. ​34​ They looked at results for each patient up to 60 hours after initiation and 
switched from use of vasopressin and terlipressin to norepinephrine after 48 hours. ​34​ The 
terlipressin group had a significantly lower requirement for norepinephrine during and after the 
infusion of terlipressin when compared to both the vasopressin combination therapy and the 
norepinephrine monotherapy group (p<0.001). ​34​ There was no significant difference in mortality 
between these groups during the duration of the study, 46.67% for terlipressin, 53.33% for 
vasopressin, and 66.67% for norepinephrine (p=0.533) but it is important to remember patients 
were only followed for 60 hours. ​34​ There was also a statistically insignificant difference in the 
amount of new onset arrhythmias, 0% in terlipressin, 6.67% in vasopressin and 26.67%  in the 
norepinephrine (p=0.054) groups respectively. ​34​ The norepinephrine and vasopressin groups both 
had statistically significant (p<0.05) increases in heart rate compared to the terlipressin 
combination therapy group. ​34 ​The norepinephrine group had a statistically significant (p<0.05) 
Right Vasopressor 27 
decrease in pH compared to the terlipressin group. ​34​ Norepinephrine use had more patients 
requiring renal replacement therapy, 53.3% compared to 26.7% in the terlipressin and 33.3% in 
the vasopressin groups, though this was not statistically significant (p=0.293). ​34​ Although many 
results showed benefits, terlipressin did cause adverse effects. Terlipressin did have a statistically 
significant drop in platelet count from baseline over time compared to vasopressin and 
norepinephrine (p<0.001). ​34​ Terlipressin also had a statistically significant (p<0.05) decrease in 
hemoglobin compared to the norepinephrine monotherapy group. ​34​  This study provides some 
evidence that low dose continuous infusion of terlipressin in combination with norepinephrine is 
as effective as norepinephrine monotherapy and vasopressin with norepinephrine combination 
therapy at increasing MAP for patients in septic shock. ​34​ Due to the small nature, limited study 
drug treatment window, and short duration of patient follow up, further studies will be needed to 
add strength to any treatment plan recommending to add terlipressin as a combination therapy for 
septic shock.  
Antidiuretic hormone analogs, terlipressin and vasopressin, have been shown to be 
effective at counteracting the hypoperfusion caused by septic shock. ​20-25,27,31-34​ There is some 
evidence to support the use of these antidiuretic hormone analogs as either combination therapy 
with norepinephrine early in septic shock ​20-25,33,34​ or as a first line vasopressor in specific patient 
populations. ​27,31-33​ The early use of these medications is associated with a quicker response of 
reaching the MAP goal and maintaining it, but more studies are needed. ​24,33 
Early Pressors 
The Surviving Sepsis Campaign modified its most recent guidelines to include a new 
Hour-1 Bundle, which now includes a rapid bolus of 30 mL/kg crystalloid infusion along with 
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giving vasopressors during or after the bolus to help achieve and maintain a MAP of 65 mmHg. ​5 
This is a change from the 2016 guidelines, which had the bolus given in the first 3 hours 
followed by subsequent boluses and then the use of vasopressors. ​3​ There is data to support that 
earlier use of the combination therapy of norepinephrine with vasopressin ​20-25​ and 
norepinephrine with terlipressin ​ 33,34​ improves outcomes. This evidence that early use of 
norepinephrine is an effective way to combat hypoperfusion but there can be detrimental effects 
if given too early or too late. ​37 
Hamzaoui et al performed a prospective observational study which looked at the use of 
early norepinephrine defined as given at some point before 6 hours after the onset of septic shock 
in 105 patients. ​35​ They found that in severe shock, early use of norepinephrine was effective at 
obtaining the MAP goal and increasing preload and contractility of the heart. ​35​ Bai et al 
performed a small retrospective non-interventional study that also showed early administration 
of norepinephrine to be beneficial. ​36​ This study classified early administration of norepinephrine 
to be within 2 hours of the onset of septic shock. ​36​ The lowest mortality, 27.5%, was associated 
with administration of norepinephrine at or before the 1 hour mark after the onset of septic 
shock. ​36​ Mortality increased with each hour of delay with mortality reaching 65% if 
norepinephrine was administered after the initial 6 hours. ​36​ They also noted a decrease in the 
total duration and dosage of norepinephrine as well as a decrease in total crystalloid fluids 
needed for the early group compared to the late group. ​36​ Early vasopressors with fluid was found 
to be beneficial in this study and indications show the earlier the administration the better for 
patient success. 
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Health care providers must be careful because not enough fluid can also be detrimental 
for patients. Martin et al found that there was a higher mortality rate associated with earlier 
norepinephrine use. ​13​ This study found survivors received more fluid overall during treatment 
compared to non-survivors, but due to the retrospective nature of this study it is unknown why 
there is this descrepency. ​13​ Too little crystalloid fluid in a patient before starting vasopressors is 
also found to be an issue by Waechter et al. ​37​ This is another retrospective observational study 
that looked at 18 years of ICU patient charts from 24 hospitals analyzing 2,849 total patients. A 
large influencer in increased mortality in this study was low amounts of fluid infused during the 
1-6 hour period after the onset of shock. ​37​ They noticed higher mortality rates when less than 500 
mL of crystalloid fluid was given within the first hour after onset of septic shock. ​37​ Mortality 
increased when given a low volume of fluid, less than 500 mL, 6.3% to 7.5% compared to a 
moderate, 1.7 L, and large, 3.7 L, amount of infused fluid. ​37​ Also found in the higher mortality 
was an association between the decrease in fluid and vasopressors given with-in the first hour. ​37 
They hypothesized that this is due to both treatment outcomes being the same, MAP greater than 
65mmHg, and therefore there is a decrease in prescribed fluids once that goal is achieved. ​37 
Waechter et al found higher mortality in septic patients if they were given vasopressors in the 
first hour of shock or after six hours after the onset of shock. ​37​ They also found that patients who 
received a low volume of fluid from 1 to 6 hours after the onset, median of 0.5 L, had a higher 
mortality. ​37​ Giving vasopressors before an adequate amount of crystalloid fluid is administered 
can be detrimental to patients.  
Decreasing the amount of crystalloid fluid used in resuscitation of septic shock patients is 
one reason for early vasopressor administration. Intravenous fluid administration is not 
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completely benign and can cause problems with fluid overload. Finding the appropriate amount 
of fluid to administer before starting vasopressors is a balancing act. McDonald et al looked at 
altering the standard approach with a limited fluids approach. ​38​ The restricted fluid resuscitation 
in suspected sepsis associated hypotension (REFRESH) was a pilot prospective randomized open 
label trial that looked at decreasing the initial crystalloid fluid given with the addition of 
vasopressors earlier in treatment. ​38​ The two arms of this study consisted of the standard bolus of 
30 mL/kg administered within the first 3 hours, another bolus of 1L followed by boluses of 500 
mL, followed by vasopressors to achieve a MAP of 65mmHg versus the restricted fluid arm 
which started vasopressors right away to achieve a MAP of 65 mmHg with fluid boluses of 250 
mL up to 1 L being administered as needed along with a maintenance fluid dose of 150mL/hr. ​38 
This protocol was from onset until 6 hours post randomization. ​38​ This small pilot study of 99 
patients showed no increased mortality, 8% in the restricted group versus 6% in the standard 
care. ​38​ The restricted care had less total time receiving vasopressors compared to the standard 
care, 21 hours versus 33 hours (p=0.13), though it is not a statistically significant decrease in 
time. ​38  
Ranjit et al performed a pilot study that also looked at restricted fluid and early 
norepinephrine use compared to the established standard of care in pediatrics. ​39​ This study 
looked at limiting fluid after the initial 30mL/kg bolus by infusing norepinephrine at 0.05-0.1 
mcg/kg/min or continuing with fluid boluses up to 40 mL/kg and then using vasopressors. ​39​ The 
study compared 27 patients who were placed in the early norepinephrine group and then the 
authors used charts from 41 previous treated patients to make the data set for the current standard 
of care group. ​39​ They noted a decrease in the volume of crystalloid fluid received in the early 
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vasopressor group compared to the standard care group at 6 hours of care, 37.4 mL/kg versus 
88.9 mL/kg (p<0.0001). ​39​ The 24 hour positive fluid balance was also significantly decreased in 
the early vasopressor group compared to the standard care group, 4.8 mL/kg versus 9.6 mL/kg 
(p<0.0001).​39​ They also found a decrease in the time patients spent on a ventilator, 1 day for 
early vasopressor versus 4 days in the standard care group (p<0.0001). ​39​ Length of stay in the 
pediatric intensive care unit was also decreased, 4 days for the early group compared to 6 days in 
the standard group (p<0.002). ​39​ There was no change in mortality between the early vasopressor 
group and the standard care group, 11.1% in the early group and 9.8% in the standard group 
(p=1).​39​ This was a small study that used historical patients as a control. ​39​ It shows that mortality 
is not increased with this change in treatment and that there might be significant benefits with 
this treatment modification. ​39  
A feasibility trial for the conservative versus liberal approach to fluid therapy of septic 
shock in intensive care (CLASSIC) trial looks at restricting fluids after the initial 30ml/kg bolus 
given. ​40​ In the fluid restriction group, patients are given boluses of 250-500 mL for many 
reasons. The reasons to give crystalloid fluid were; if their lactate level was above 4 mmol/L, if 
MAP remains below 50 mmHg despite norepinephrine, if there was mottling above the knee, or 
oliguria was present in the first 2 hours of randomization. ​40​ The standard of care group was given 
fluid boluses as long as there was a hemodynamic improvement after the bolus. ​40​ This feasibility 
study randomized 151 and patients showed no increase in mortality, 33% in the fluid restricted 
group and 41% in the standard care group (p=0.32). ​40​ Adverse reactions also had no change, 
specifically cardiac ischemia 4% versus 12% (p=0.11), and acute kidney injury 37% versus 54%( 
p=0.03) in the restricted and standard care groups respectively. ​3,12​ There was also no change in 
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the amount of renal replacement therapy needed in the restricted group, 92%, versus the standard 
care group, 92% (p=0.7). ​40​ The need for ventilator support was also unchanged, 79% in the 
restricted versus 72% in the standard care (p=0.48). ​40​ These small studies demonstrates that 
decreased fluids and earlier use of vasopressors are not detrimental to the patients and may 
provide some benefit. ​38-40​ Further, larger scale studies are needed to verify that this treatment 
change is safe, beneficial, and to more accurately evaluate how effective it is before it can be 
considered as a new standard of care or replace old guidelines. 
Early administration of vasopressors has been shown to decrease morbidity and mortality 
when given in the correct circumstance. Too early is detrimental and too late has unfavorable 
outcomes as well. Along with timing the administration of vasopressors is the administration of 
crystalloid fluids, not enough fluid is hazardous and too much can have deleterious effects. 
Finding the right balance of fluid administration and timing of vasopressors, all while trying to 
limit the time that a patient is in a hypoperfused state is difficult but imperative to helping them 
survive. 
Discussion 
Sepsis continues to have a high mortality rate despite numerous changes and 
improvements to care. The standardizing of sepsis care by the Surviving Sepsis Campaign has 
helped to decrease mortality but many of their early care guidelines are weak recommendations 
with weak evidential support. It is unfortunate that these guidelines are not definitive because 
these early treatments are essential to help stabilize patients and regain perfusion to their tissues. ​3 
It seems logical that the quickest way to return perfusion would be the best treatment for patients 
in septic shock. However, defining this treatment can be difficult as there are many factors at 
Right Vasopressor 33 
play in how a patient will respond to a given treatment. A recent retrospective analysis by 
Seymour et al found that there are four phenotypes of patients, alpha, beta, gamma and delta. ​41 
These phenotypes are based on how they respond to vasopressors and which organ systems have 
been effected. ​41 ​Mortality rates change based on these phenotypes, with alpha having the best 
mortality and delta the worst. ​41​ Patients are complex beings with complex and sometimes 
unknown medical histories that need to be considered by health care providers when considering 
how to move forward with treatment. 
 ​A patient’s past medical history plays a significant role in the severity and progression of 
sepsis ​2,41​ as well as deciding which vasopressor they should ​receive. ​10,11,20-25​ For example, the 
evaluated studies looking at vasopressin did not include patients with a history of severe 
congestive heart failure due to the adverse reactions of vasopressin in patients with heart 
failure. ​20-25​ Congestive heart failure patients are also the patients that a provider is most 
concerned about giving massive amounts of fluids to due to the risk of pulmonary edema. These 
circumstances limit who can receive which therapy, which plays a contributing factor to the 
weakness of the current guidelines and recommendations.  
Another factor that appears to affect vasopressor therapy is how severe the septic shock is 
at the initiation of the vasopressor treatment. Use of the combination of vasopressin and 
norepinephrine was more effective when the patient was in a state of less severe septic 
shock. ​10,11,21-23,26​ Patients being treated with vasopressors later required higher doses and had 
higher associated mortality. Higher doses are also associated with a higher frequency of more 
severe adverse reactions. ​9,12-14  
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Where the initial infection is located is another major contributing factor when 
determining treatment. Many of the studies noted or cited the initial source of the infection, with 
pneumonia and intra abdominal being the most common, but, unfortunately, none investigated 
this further. ​9,15,16,24,32-34​ It is not listed which sources of infection tend to be more serious, or if 
there is any major differences caused by the source sites. ​9,15,16,24,32-34​ The studies do not explain if 
certain sources have a higher mortality or are less likely to respond to or need higher doses of 
vasopressors.​9,15,16,24,32-34​ This may be due to the smaller size of these studies or the retrospective 
nature of the larger studies. ​9,15,16,24,32-34​ According to UpToDate, mortality is affected by the 
location of the infection site and the type of microbe causing the initalinfection. ​2​  In both animal 
trials that were evaluated, the studies had placed their subjects into septic shock using fecal 
implantation into the peritoneal cavity. ​29,30​ How transferable to other sources of infection are 
these evaluations? There is data that shows race effects norepinephrine dosing, ​16​ and the type and 
site of infection affect the mortality of patients. ​2 ​Do the different sites and types of infection 
affect how a patient will respond to treatments? These are areas that need to be further studied as 
this appears to be a multifactorial disease process.  
Even before determining which therapy is best for a patient, health care providers must 
achieve their initial goal: obtaining a MAP greater than 65 mmHg. Furthermore, attaining this 
goal as early as possible is crucial. Establishing tissue perfusion early is associated with 
decreased mortality and use of vasopressors to achieve this is shown to be fairly consistent and 
beneficial. ​35-40​ The timeline for starting vasopressors is currently being debated. Waechter et al 
found that too early can be detrimental, but too late can be just as detrimental. One aspect found 
to be detrimental with early administration of vasopressors is that there is a lack of crystalloid 
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bolus given. ​37​ There is a consensus that starting with a fluid bolus before administering 
vasopressors is an appropriate step. The Surviving Sepsis Campaign guidelines for the Hour-1 
Bundle include a bolus of 30 mL/kg rapid infusion for the treatment of hypotension or a lactate 
greater than 4 mmol/L. ​5​ The administration of vasopressors shows to have a beneficial effect 
after administration of at least 1,000 mL of the initial 30 mL/kg bolus. ​36-39​ Getting the first liter 
of fluid in and starting vasopressors is also most beneficial if done between hour 1 and hour 6 
after the onset of shock, with some research pointing to between hour 1 and 2 as being the most 
beneficial. ​35-37​ Quick recognition of the signs of septic shock allows for a fast initiation of fluid 
boluses and earlier administration of vasopressors, currently norepinephrine, to combat the 
hypoperfused state. 
Norepinephrine as a monotherapy is the current standard of care, though at higher doses 
it is associated with increased frequency of adverse effects, increased severity of adverse effects, 
and higher mortality. ​9,12-14,37​ Compared to other monotherapy vasopressors, norepinephrine has 
similar if not better rates of mortality, especially compared to dopamine, vasopressin, terlipressin 
and epinephrine. ​10,32,34​ Since monotherapy does not always work or isn’t beneficial to particular 
patients there needs to be other safe and effective alternative options. Patients who are in septic 
shock that are unresponsive to both fluid boluses and norepinephrine are considered to be in a 
more severe state of shock. ​2-4​ The unresponsiveness could be due to a late presentation, a delay 
in care, or a rapidly progressing disease process. ​2-4​ Early detection and appropriate treatment is a 
key to decreasing mortality. ​3,5​ This becomes apparent when looking at adding vasopressin to 
norepinephrine in the treatment of septic shock. ​20-25  
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In general, vasopressin as monotherapy has no effect on mortality compared to 
norepinephrine monotherapy. ​10,18-26​ Used alone there is no effect, but vasopressin used in 
combination therapy with norepinephrine and administered in early shock has shown a decrease 
in mortality compared to norepinephrine montherapy. ​10,19,21,22,24,26​ This specific subgroup benefits 
from the early recognition of sepsis and the quick establishment of treatment. This subgroup of 
the early presentation of septic shock does not fall into the current Sepsis 3.0 definition, 
specifically because the definition dictates patients need to have a lactate of less than or equal to 
2 mmol/L. ​21​ Vasopressin may contribute another benefit with treating septic shock. There is 
suspicion and some i​n vitro ​ data to support that norepinephrine may inhibit the body’s immune 
response in fighting off an infection and that vasopressin does not have the same effect. ​42​ The 
addition of vasopressin to norepinephrine has shown to be beneficial unless patients cannot 
receive vasopressin due to abnormal cardiac function, such as severe congestive heart failure. 
Patients in septic shock with preexisting cardiac problems do have other options for a 
combination therapy. This subgroup of patients could receive norepinephrine and dobutamine as 
a dual therapy to achieve tissue reperfusion. ​10,11​ Looking at different combinations and how it 
affects subpopulations of patients is important to determine the best option for each patient and 
providing stronger, clearer guidelines moving forward. 
Terlipressin, with its long acting and selective V1 agonist, seems like it would be a great 
choice in treating the hypotension associated with septic shock but for the general population of 
patients it appears to have no added benefits over norepinephrine. ​31,32,34​ Terlipressin monotherapy 
may have a place in a subset of patients as shown in certain studies. For patients with a previous 
medical history of liver cirrhosis, a low dose infusion was as effective at obtaining and 
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maintaining the MAP goal and also had the added benefit of less severe effects on variceal 
bleeding. ​31​ Combination therapy of terlipressin and norepinephrine shows some promise with 
improving mortality, and achieving tissue perfusion quicker and maintaining it longer compared 
to norepinephrine alone. ​33​ The problem with terlipressin is that high dose bolus administrations 
are associated with higher incidence of severe adverse reactions, specifically digital ischemia and 
severe diarrhea. ​32​ Another problem with terlipressin is that it is currently not approved for use in 
the United States. 
Conclusion 
Early identification of sepsis, septic shock, and even the pre-shock stage allows for 
expedited therapy. These patients are very ill and can decompensate very rapidly if they are not 
treated quickly and appropriately. The initial fluid bolus recommended by the Surviving Sepsis 
Campaign may not be supported by high quality evidence, but the evidence is there, although not 
strong, for the recommendation to remain in place. There is currently a randomized clinical trial 
in process, Crystalloid Liberal Or Vasopressors Early Resuscitation in Sepsis (CLOVERS), 
looking at giving patients only 1 L of crystalloid fluid before starting vasopressors compared to 
the current practice of up to 3 L before initiating vasopressors. ​43​ Even though it is considered 
weak evidence, giving a fluid bolus initially before starting vasopressors appears effective and 
helps to decrease mortality.  
Along with early recognition and early treatment comes the use of combination 
vasopressor therapy versus norepinephrine monotherapy. Monotherapy with norepinephrine is 
very effective at treating the hypoperfusion state. That being said, vasopressin and terlipressin as 
initial monotherapy appears to be just as effective and may be a better option in certain patient 
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subgroups. Unfortunately, terlipressin is not currently approved to be used on human patients in 
the United States. 
 For patients who are unresponsive to monotherapy, it is important to start combination 
therapy early to limit the total dose of norepinephrine. Combination therapy should be based on 
the patient, their current situation, and their medical history. Patients who do not yet meet the 
criteria for septic shock based on the sepsis 3.0 criteria, i.e. lactate less than 2 mmol/L, could 
benefit from combination therapy with low dose vasopressin and norepinephrine to achieve 
tissue perfusion after receiving an initial fluid bolus. The effectiveness of early use of 
combination vasopressin therapy is based on secondary evaluation of randomized control trials. 
Even though the data from these secondary evaluations is promising, further confirmation 
through randomized control trials should be performed to verify this treatment’s effectiveness 
versus the current standard of care for this patient set. 
For the best benefit in patients suffering from septic shock, the most important takeaway 
is early recognition of their deterioration followed by early fluids and vasopressors as soon as an 
initial fluid bolus is onboard. This treatment algorithm, using crystalloid fluid boluses and early 
norepinephrine in combination with other vasopressors like vasopressin, terlipressin, or 
dobutamine, is currently the most effective way known to counteract the hypoperfused state 
caused by septic shock. 
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